The prevalence of EGFR-activating exon 20 insertions (ex20ins) is only 4%–10% in NSCLC patients (Yasuda et al., 2012; Arcila et al., 2013; Oxnard et al., 2013). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.